Inhibition of HH signaling pathway in vivo decreased tumor growth and induced E-Cadherin expression.300,301 Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) are widely used as first line therapy for NSCLC. This evidence concerns the gene EGFR and non-small cell lung carcinoma.